Cancer Antibodies

Cancer Antibodies is a U.S.-based nonprofit cancer research organization focused on discovering tumor-specific cell-surface antigens and generating matching therapeutic antibodies. Its core technology, the Oncotope Platform, is designed to identify novel cancer-specific antigenic sites that are absent from normal cells, with the goal of enabling more precise and less toxic cancer therapies. The organization has reported target discovery work in breast cancer, triple-negative breast cancer, prostate cancer, and melanoma, and has highlighted ZIP7 as one emerging target. Cancer Antibodies appears to operate primarily as a discovery-stage and translational research organization rather than a clinical-stage drug developer. It also engages external collaborators to validate targets and advance antibody-based oncology applications.